CHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE

Objective: Compared with other cytogenetic acute myeloid leukemia (AML) groups, patients with core-binding factor AML (CBF-AML) are considered as a favorable AML risk group based on their high remission rate and survival probabilities. However, up to 30-40% of these patients can still relapse after...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Volkan KÖSE, Dilek KAÇAR, Özlem ARMAN BİLİR, Ayça KOCA YOZGAT, Hüsniye Neşe YARALI
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2021
Materias:	Diseases of the blood and blood-forming organs RC633-647.5
Acceso en línea:	https://doaj.org/article/c730cbd83d9b47a2b003989b8214ddab
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:c730cbd83d9b47a2b003989b8214ddab
record_format	dspace
spelling	oai:doaj.org-article:c730cbd83d9b47a2b003989b8214ddab2021-11-10T04:38:21ZCHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE2531-137910.1016/j.htct.2021.10.1076https://doaj.org/article/c730cbd83d9b47a2b003989b8214ddab2021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921012232https://doaj.org/toc/2531-1379Objective: Compared with other cytogenetic acute myeloid leukemia (AML) groups, patients with core-binding factor AML (CBF-AML) are considered as a favorable AML risk group based on their high remission rate and survival probabilities. However, up to 30-40% of these patients can still relapse after standard intensive induction and consolidation chemotherapy. Methodology: From 2004 to 2020, 147 AML patients reviewed. Ten of 147 patients were followed up with t(8;21) chromosomal anomaly. The t(8;21)(q22;q22) was detected by reverse transcription polymerase chain reaction (RT-PCR) and/or floresan in situ hibridizasyon (FISH). We analyzed patients’ demographic data: sex, white blood cell count at diagnosis, central nervous system status, additional cytogenetic anomaly and recurrence rates, stem cell transplant status and survival rates. Results: Two of 10 patients were female. The median age was 10 years (3-17 years). Median followup was 36 months (2-114 months). The mean white blood cell count of 10 patients was 21.5 (× 109/l) at diagnosis. One out of 10 patients had granulocytic sarcoma and 2 had central nervous system involvement. Additional cytogenetic anomalies were detected in 90% of the patients, of which 2 relapsed and 3 died. One patient received hematopoietic stem cell transplantation and died because of HSCT complications. Conclusion: Recent studies show that CBF-AML includes different groups with different clinical outcomes. We found that 50% of our patients achieved complete remission and 50% experienced relapsed disease or death. After we were able to monitor the t(8;21) level with RT-PCR, we diagnosed relapsed disease in 1 patient with additional cytogenetic anomaly. RT-PCR is essential for optimal handling of these patients to predict patients’ relapse risk and to detect minimal residual disease.Volkan KÖSEDilek KAÇARÖzlem ARMAN BİLİRAyça KOCA YOZGATHüsniye Neşe YARALIElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S58- (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Diseases of the blood and blood-forming organs RC633-647.5
spellingShingle	Diseases of the blood and blood-forming organs RC633-647.5 Volkan KÖSE Dilek KAÇAR Özlem ARMAN BİLİR Ayça KOCA YOZGAT Hüsniye Neşe YARALI CHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE
description	Objective: Compared with other cytogenetic acute myeloid leukemia (AML) groups, patients with core-binding factor AML (CBF-AML) are considered as a favorable AML risk group based on their high remission rate and survival probabilities. However, up to 30-40% of these patients can still relapse after standard intensive induction and consolidation chemotherapy. Methodology: From 2004 to 2020, 147 AML patients reviewed. Ten of 147 patients were followed up with t(8;21) chromosomal anomaly. The t(8;21)(q22;q22) was detected by reverse transcription polymerase chain reaction (RT-PCR) and/or floresan in situ hibridizasyon (FISH). We analyzed patients’ demographic data: sex, white blood cell count at diagnosis, central nervous system status, additional cytogenetic anomaly and recurrence rates, stem cell transplant status and survival rates. Results: Two of 10 patients were female. The median age was 10 years (3-17 years). Median followup was 36 months (2-114 months). The mean white blood cell count of 10 patients was 21.5 (× 109/l) at diagnosis. One out of 10 patients had granulocytic sarcoma and 2 had central nervous system involvement. Additional cytogenetic anomalies were detected in 90% of the patients, of which 2 relapsed and 3 died. One patient received hematopoietic stem cell transplantation and died because of HSCT complications. Conclusion: Recent studies show that CBF-AML includes different groups with different clinical outcomes. We found that 50% of our patients achieved complete remission and 50% experienced relapsed disease or death. After we were able to monitor the t(8;21) level with RT-PCR, we diagnosed relapsed disease in 1 patient with additional cytogenetic anomaly. RT-PCR is essential for optimal handling of these patients to predict patients’ relapse risk and to detect minimal residual disease.
format	article
author	Volkan KÖSE Dilek KAÇAR Özlem ARMAN BİLİR Ayça KOCA YOZGAT Hüsniye Neşe YARALI
author_facet	Volkan KÖSE Dilek KAÇAR Özlem ARMAN BİLİR Ayça KOCA YOZGAT Hüsniye Neşe YARALI
author_sort	Volkan KÖSE
title	CHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE
title_short	CHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE
title_full	CHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE
title_fullStr	CHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE
title_full_unstemmed	CHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE
title_sort	characteristics and outcome of t(8;21)-positive childhood acute myeloid leukemia: a single institution's experience
publisher	Elsevier
publishDate	2021
url	https://doaj.org/article/c730cbd83d9b47a2b003989b8214ddab
work_keys_str_mv	AT volkankose characteristicsandoutcomeoft821positivechildhoodacutemyeloidleukemiaasingleinstitutionsexperience AT dilekkacar characteristicsandoutcomeoft821positivechildhoodacutemyeloidleukemiaasingleinstitutionsexperience AT ozlemarmanbilir characteristicsandoutcomeoft821positivechildhoodacutemyeloidleukemiaasingleinstitutionsexperience AT aycakocayozgat characteristicsandoutcomeoft821positivechildhoodacutemyeloidleukemiaasingleinstitutionsexperience AT husniyeneseyarali characteristicsandoutcomeoft821positivechildhoodacutemyeloidleukemiaasingleinstitutionsexperience
_version_	1718440596776943616

CHARACTERISTICS AND OUTCOME OF T(8;21)-POSITIVE CHILDHOOD ACUTE MYELOID LEUKEMIA: A SINGLE INSTITUTION'S EXPERIENCE

Ejemplares similares